Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis.
Hedin CRH, Sado G, Ndegwa N, Lytvyak E, Mason A, Montano-Loza A, Gerussi A, Saffioti F, Thorburn D, Nilsson E, Larsson G, Moum BA, van Munster KN, Ponsioen CY, Levy C, Nogueira NF, Bowlus CL, Gotlieb N, Shibolet O, Lynch KD, Chapman RW, Rupp C, Vesterhus M, Jørgensen KK, Rorsman F, Schramm C, Sabino J, Vermeire S, Zago A, Cazzagon N, Marschall HU, Ytting H, Ben Belkacem K, Chazouilleres O, Almer S; International PSC Study Group; Bergquist A. Hedin CRH, et al. Among authors: ytting h. Clin Gastroenterol Hepatol. 2020 Sep;18(10):2295-2304.e2. doi: 10.1016/j.cgh.2020.02.014. Epub 2020 Feb 15. Clin Gastroenterol Hepatol. 2020. PMID: 32068151
Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: An international cohort study.
de Vries EM, de Krijger M, Färkkilä M, Arola J, Schirmacher P, Gotthardt D, Goeppert B, Trivedi PJ, Hirschfield GM, Ytting H, Vainer B, Buuren HR, Biermann K, Harms MH, Chazouilleres O, Wendum D, Kemgang AD, Chapman RW, Wang LM, Williamson KD, Gouw AS, Paradis V, Sempoux C, Beuers U, Hübscher SG, Verheij J, Ponsioen CY. de Vries EM, et al. Among authors: ytting h. Hepatology. 2017 Mar;65(3):907-919. doi: 10.1002/hep.28963. Epub 2017 Jan 11. Hepatology. 2017. PMID: 27880989
Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune Hepatitis.
Efe C, Hagström H, Ytting H, Bhanji RA, Müller NF, Wang Q, Purnak T, Muratori L, Werner M, Marschall HU, Muratori P, Gunşar F, Klintman D, Parés A, Heurgué-Berlot A, Schiano TD, Cengiz M, May-Sien Tana M, Ma X, Montano-Loza AJ, Berg T, Verma S, Larsen FS, Ozaslan E, Heneghan MA, Yoshida EM, Wahlin S. Efe C, et al. Among authors: ytting h. Clin Gastroenterol Hepatol. 2017 Dec;15(12):1950-1956.e1. doi: 10.1016/j.cgh.2017.06.001. Epub 2017 Jun 8. Clin Gastroenterol Hepatol. 2017. PMID: 28603052
Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases.
Lynch KD, Chapman RW, Keshav S, Montano-Loza AJ, Mason AL, Kremer AE, Vetter M, de Krijger M, Ponsioen CY, Trivedi P, Hirschfield G, Schramm C, Liu CH, Bowlus CL, Estes DJ, Pratt D, Hedin C, Bergquist A, de Vries AC, van der Woude CJ, Yu L, Assis DN, Boyer J, Ytting H, Hallibasic E, Trauner M, Marschall HU, Daretti LM, Marzioni M, Yimam KK, Perin N, Floreani A, Beretta-Piccoli BT, Rogers JK; International Primary Sclerosing Cholangitis Study Group (IPSCSG); Levy C. Lynch KD, et al. Among authors: ytting h. Clin Gastroenterol Hepatol. 2020 Jan;18(1):179-187.e6. doi: 10.1016/j.cgh.2019.05.013. Epub 2019 May 14. Clin Gastroenterol Hepatol. 2020. PMID: 31100458 Free PMC article.
Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis.
Efe C, Taşçilar K, Henriksson I, Lytvyak E, Alalkim F, Trivedi H, Eren F, Eliasson J, Beretta-Piccoli BT, Fischer J, Calişkan AR, Chayanupatkul M, Coppo C, Ytting H, Purnak T, Muratori L, Werner M, Muratori P, Rorsman F, Önnerhag K, Günşar F, Nilsson E, Heurgué-Berlot A, Güzelbulut F, Demir N, Gönen C, Semela D, Aladağ M, Kiyici M, Schiano TD, Montano-Loza AJ, Berg T, Ozaslan E, Yoshida EM, Bonder A, Marschall HU, Wahlin S. Efe C, et al. Among authors: ytting h. Am J Gastroenterol. 2019 Jul;114(7):1101-1108. doi: 10.14309/ajg.0000000000000290. Am J Gastroenterol. 2019. PMID: 31241547
Second-line and third-line therapy for autoimmune hepatitis: A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group.
Lohse AW, Sebode M, Jørgensen MH, Ytting H, Karlsen TH, Kelly D, Manns MP, Vesterhus M; European Reference Network on Hepatological Diseases (ERN RARE-LIVER); International Autoimmune Hepatitis Group (IAIHG). Lohse AW, et al. Among authors: ytting h. J Hepatol. 2020 Dec;73(6):1496-1506. doi: 10.1016/j.jhep.2020.07.023. Epub 2020 Jul 21. J Hepatol. 2020. PMID: 32707224 Review.
Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group.
Pape S, Snijders RJALM, Gevers TJG, Chazouilleres O, Dalekos GN, Hirschfield GM, Lenzi M, Trauner M, Manns MP, Vierling JM, Montano-Loza AJ, Lohse AW, Schramm C, Drenth JPH, Heneghan MA; International Autoimmune Hepatitis Group (IAIHG) collaborators(‡). Pape S, et al. J Hepatol. 2022 Apr;76(4):841-849. doi: 10.1016/j.jhep.2021.12.041. Epub 2022 Jan 20. J Hepatol. 2022. PMID: 35066089 Free article.
50 results